Your browser doesn't support javascript.
loading
Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao, Jiaojiao; Fan, Wenhua; Li, Yizhuo; Tang, Ranran; Tian, Chunfang; Yang, Qian; Zhu, Tianhua; Diao, Chaoliang; Hu, Sheng; Chen, Manyu; Guo, Ping; Long, Qian; Zhang, Changlin; Qin, Ge; Yu, Wendan; Chen, Miao; Li, Liren; Qin, Lijun; Wang, Jingshu; Zhang, Xiuping; Ren, Yandong; Zhou, Penghui; Zou, Lijuan; Jiang, Kui; Guo, Wei; Deng, Wuguo.
Afiliación
  • Hao J; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Fan W; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Li Y; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Tang R; Nanjing Maternity and Child Health Care Hospital, Women's Hospital of Nanjing Medical University, Nanjing, China.
  • Tian C; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Yang Q; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Zhu T; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Diao C; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Hu S; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Chen M; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Guo P; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Long Q; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Zhang C; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Qin G; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Yu W; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Chen M; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Li L; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Qin L; Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
  • Wang J; Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
  • Zhang X; Cloud Health Genomics Ltd, Shanghai, China.
  • Ren Y; Cloud Health Genomics Ltd, Shanghai, China.
  • Zhou P; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • Zou L; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Jiang K; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China. kuijiang501@sina.com.
  • Guo W; Institute of Cancer Stem Cells and The Second Affiliated Hospital, Dalian Medical University, Dalian, China. wei1015@dmu.edu.cn.
  • Deng W; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China. dengwg@sysucc.org.cn.
J Exp Clin Cancer Res ; 38(1): 48, 2019 Feb 04.
Article en En | MEDLINE | ID: mdl-30717768
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Células Madre Neoplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Telomerasa / Proteínas Proto-Oncogénicas B-raf / Inhibidores de Proteínas Quinasas / Óxido Nítrico Sintasa de Tipo II / Vemurafenib / Melanoma / Melatonina Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Células Madre Neoplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Telomerasa / Proteínas Proto-Oncogénicas B-raf / Inhibidores de Proteínas Quinasas / Óxido Nítrico Sintasa de Tipo II / Vemurafenib / Melanoma / Melatonina Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: J Exp Clin Cancer Res Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido